|
MechanismPeptidase family A1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date30 Mar 1976 |
/ Not yet recruitingPhase 1 AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
100 Clinical Results associated with Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA
0 Patents (Medical) associated with Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA
100 Deals associated with Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA
100 Translational Medicine associated with Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA